Home › Funds › Versant Venture Management, LLC › CTNM

Versant Venture Management, LLC position in CTNM

CONTINEUM THERAPEUTICS INC · Health Care

Versant Venture Management, LLC reported holding 1,292,628 shares of CTNM (CONTINEUM THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$17.3M, representing 15.90% of its reported portfolio and ranking #3 among its reported holdings. Versant Venture Management, LLC has disclosed CTNM holdings in 10 of the last 10 reported quarters, going back to Q2 2024.

Latest position (Q3 2026)1.29M sh
Reported value held$17.35M
Portfolio Weight15.90%
First reportedQ2 2024
Last changeAdd
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Versant Venture Management, LLC's CTNM position evolved

Versant Venture Management, LLC first disclosed a stake in CTNM in Q2 2024 at 918,163 shares (US$16.2M). The position peaked in Q3 2024 at 918,163 shares, worth US$17.6M. Across 10 filings, Versant Venture Management, LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 7 time(s). The most recent filing (Q3 2026) shows 1,292,628 shares valued at US$17.3M — an increase of 750,000 shares quarter over quarter.. Notable position changes include a 41% trim in Q2 2025 (shares rose 196% over the following quarter), a 138% increase in Q3 2026 (shares fell 27% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2024 918.16K $16.17M New
Q3 2024 918.16K $17.57M Hold
Q4 2024 918.16K $13.45M Hold
Q1 2025 918.16K $6.41M Hold
Q2 2025 542.63K $2.15M Reduce
Q3 2025 542.63K $6.38M Hold
Q4 2025 542.63K $6.20M Hold
Q1 2026 542.63K $7.09M Hold
Q2 2026 542.63K $8.89M Hold
Q3 2026 1.29M $17.35M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CTNM and 13F data

CTNM (CONTINEUM THERAPEUTICS INC) is a Health Care company. 55 other funds we track also report a position in CTNM — the largest reported positions include MONTANOVA CAPITAL, LLC (US$46.6M), JOHNSON & JOHNSON (US$26.6M), GREAT POINT PARTNERS LLC (US$15.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CTNM

All CTNM fund holders →

FAQ

How long has Versant Venture Management, LLC held CTNM?

Versant Venture Management, LLC has disclosed CTNM holdings in 10 of the last 10 reported quarters, going back to Q2 2024.

What is Versant Venture Management, LLC's current position in CTNM?

As of Q3 2026, Versant Venture Management, LLC holds 1.29M shares of CTNM (CONTINEUM THERAPEUTICS INC), valued at $17.35M, representing 15.90% of its reported portfolio and ranking #3.

Has Versant Venture Management, LLC been buying or selling CTNM?

In the latest 13F filing (Q3 2026), Versant Venture Management, LLC increased its position in CTNM. The position peaked in Q3 2024 at 918.16K shares.

Which other funds hold CTNM?

Other major institutional holders of CTNM include MONTANOVA CAPITAL, LLC, JOHNSON & JOHNSON, GREAT POINT PARTNERS LLC, among 55 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.